Jun 23, 2026, 05:55 UTC
The European Commission approved Sanofi's Cenrifki for treating non-relapsing secondary progressive multiple sclerosis in adults.
Source:Jun 10, 2026, 15:51 UTC
Kymera Therapeutics starts patient dosing in a phase I study of KT-485 for hidradenitis suppurativa, triggering a $20 million milestone payment from Sanofi.
Source:Jun 10, 2026, 14:31 UTC
Sanofi halted a Phase 3 study of its drug riliprubart after an interim analysis showed the therapy was not effective.
Jun 4, 2026, 09:55 UTC
Sanofi launched its 2026 global employee stock purchase plan, Action 2026, offering shares at a 20% discount to approximately 75,000 employees across 52 countries.
Source:
← PreviousPage 2